Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00864721 · ClinicalTrials.gov registry record · Phase 2
Sunitinib Non Small Cell Lung Cancer Patients Over 70
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by US Oncology Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 13
- Study locations
NCT00864721: Completed Phase 2 study of Non-Small Cell Lung Cancer, sponsored by US Oncology Research.
NCT00864721 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by US Oncology Research. The registered enrollment target is 63 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 13 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00864721, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by US Oncology Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.
Primary Outcome
Disease control rate = CR + PR + SD\>=6-weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. Stable Disease (SD) is defined as persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
Conditions Studied
Interventions
- DRUG Sutent
Study Locations (13)
Texas
- Texas Oncology - Arlington South - Arlington
- Texas Oncology, P.A. - Bedford - Bedford
- Methodist Charlton Cancer Ctr. - Dallas
- Texas Cancer Center of Mesquite - Mesquite
- Texas Oncology Cancer Care and Research Center - Waco
Florida
- Ocala Oncology Center - Ocala
- Cancer Centers of Florida, P.A. - Ocoee
Minnesota
- Minnesota Oncology Hematology, P.A. - Minneapolis
North Carolina
- Cancer Centers of North Carolina - Raleigh
Oregon
- Willamette Valley Cancer Institute and Research Center - Eugene
South Carolina
- Cancer Centers of the Carolinas - Greenville
Virginia
- Virginia Oncology Associates - Norfolk
Washington
- Yakima Valley Mem Hosp/North Star Lodge - Yakima
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
What the finished NCT00864721 record still lists
NCT00864721 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sutent is the first listed.
NCT00864721 lists 13 locations in 8 states (Texas, Florida, Minnesota).
Frequently Asked Questions
What is clinical trial NCT00864721 about?
NCT00864721 is a clinical study titled "Sunitinib Non Small Cell Lung Cancer Patients Over 70". The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.
What is the current status of trial NCT00864721?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2009-02. Estimated completion is 2012-07.
What conditions does trial NCT00864721 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT00864721?
The interventions under investigation include: Sutent (DRUG).
Who is sponsoring clinical trial NCT00864721?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00864721 being conducted?
This trial has 13 study locations across Florida, Minnesota, North Carolina, Oregon, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00864721's enrollment target sits among peer trials
63 308th of 454 higher than 146 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia